Abbott Laboratories Reports $12.6 Billion in Q2 Sales, Driven by Exact Sciences Acquisition

Abbott Laboratories reported significant financial results for the second quarter and first half of 2026, with net sales reaching $12.6 billion and $23.8 billion, respectively, marking increases of 13% and 10.5% compared to the same periods in 2025. The growth was primarily driven by the acquisition of Exact Sciences, which contributed approximately $1 billion in sales since its acquisition on March 23, 2026. The company's operating earnings for the second quarter were $1.7 billion, down from $2.1 billion in the prior year, while net earnings fell to $928 million from $1.8 billion, reflecting increased costs associated with the acquisition and higher operational expenses.

In terms of operational metrics, Abbott's research and development (R&D) expenses rose by 22.9% to $892 million in the second quarter, largely due to the integration of Exact Sciences and ongoing investments in various development programs. Selling, general, and administrative (SG&A) expenses also increased significantly, up 30.3% to $4 billion in the second quarter, driven by integration costs and higher marketing expenditures. The gross profit margin slightly decreased to 52.5% from 52.7% year-over-year, attributed to higher intangible amortization expenses and increased operational costs.

Abbott's acquisition of Exact Sciences for approximately $20.6 billion was a pivotal strategic move, funded primarily through the issuance of $20 billion in long-term debt. This acquisition is expected to enhance Abbott's position in the cancer diagnostics market, adding products such as Cologuard® and Oncotype DX® to its portfolio. The integration of Exact Sciences is anticipated to yield synergies and growth opportunities, although it has also contributed to increased debt levels and operational costs in the short term.

Geographically, Abbott's sales in the U.S. rose by 22% in the second quarter, while international sales increased by 7.5%. The company reported strong performance in its Medical Devices and Diagnostic Products segments, with sales growth of 9% and 42.3%, respectively, driven by existing product sales and the addition of Exact Sciences. However, Nutritional Products experienced a decline, with sales down 3.1% in the second quarter, reflecting lower volumes in the U.S. pediatric nutrition segment.

Looking ahead, Abbott anticipates continued growth driven by the integration of Exact Sciences and ongoing demand for its medical devices and diagnostic products. The company expects to recognize a significant portion of its remaining performance obligations, estimated at $6.2 billion in the Diagnostic Products segment, over the next two years. Despite the challenges posed by increased operational costs and market competition, Abbott remains committed to its strategic initiatives and maintaining its investment-grade credit rating.